Your info will never be shared with a third-party
Allegro Press Releases
Allegro Ophthalmics Completes Enrollment in DEL MAR Phase 2b, Stage 2 Clinical Trial of Luminate® for the Treatment of Diabetic Macular Edema
December 15, 2016
William J. Link, PhD, Joins Allegro Ophthalmics’ Board of Directors
November 21, 2016
Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
October 13, 2016
Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate® for Non-Proliferative Diabetic Retinopathy
October 03, 2016
Allegro Ophthalmics Announces Two Executive Promotions
March 15, 2016
Vision & Mission
Our vision at Allegro Ophthalmics is to bring new therapies to market to ensure that people living with diabetes and age-related macular degeneration retain their vision and do not suffer ...
Allegro in the News
-
“New Study Affirms Promise of Anti-Integrin Drug for DME”
READ MORE >> -
“Point/Counterpoint: What is the single most difficult aspect of launching your own company or bringing your product to market?”
READ MORE >> -
“Breaking Bridges With Integrin Therapy”
READ MORE >> -
“The Promise of Integrin Receptors for Treating Vitreoretinal Disorders”
READ MORE >> -
“Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications?”
READ MORE >>